STAT+: HHS green lights six peptides, despite concerns from FDA scientists

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. I have a cold again. Cure it, science. HHS opens peptide floodgates, despite concerns from FDA scientists The Trump administration is giving the peptide craze a regulatory boost. HHS issued a policy allowing licensed pharmacies and physicians to temporarily compound six experimental peptides, including the popular injury-recovery duo BPC-157 and TB-500, without fear of federal enforcement, STAT’s Margaret Manto writes. This comes despite objections from FDA career scientists who say there’s scant evidence the substances are safe or effective. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe